Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, expanding its DispersinB® applications
Kane Biotech has entered into collaborations with Dr. James Doub and the University of Texas Medical Branch to investigate the application of DispersinB® for treating Prosthetic Joint Infections (PJI). Supported by funding from the National Institutes of Health (NIH), the research aims to address crucial challenges in treating PJIs, which affect 1-2% of prostheses and are projected to cost the U.S. healthcare system $1.62 billion in 2020 alone. CEO Marc Edwards emphasized the importance of these collaborations for advancing treatment strategies, highlighting the distinct advantages of DispersinB®.
- Collaboration with prestigious institutions enhances credibility and research potential.
- DispersinB® shows promise for more effective treatment of Prosthetic Joint Infections.
- Potential NIH funding could provide vital financial support for research.
- Addressing significant healthcare costs related to PJIs may attract investor interest.
- None.
Bacterial biofilms on prostheses limit conventional antibiotic treatments of biofilm-based infections
WINNIPEG, Manitoba, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces that it has signed collaboration agreements with Dr. James Doub, MD, Assistant Professor of Medicine, University of Maryland School of Medicine’s Institute of Human Virology, and the University of Texas Medical Branch (UTMB) to study the use of DispersinB® with Prosthetic Joint Infection (PJI) patients. The group is securing funding from the National Institutes of Health (NIH) for pre-clinical work to be done by Josh Wenke, a Professor in the Department of Orthopedic Surgery and Rehabilitation at UTMB.
PJI’s are one of the most serious complications of joint replacement surgery. Conservative estimates are that approximately 1–
“These collaborations are of utmost importance given our shared strategies for managing complex musculoskeletal infections and finding cures for the debilitating morbidity associated with PJI. We are highly optimistic of advancing this field scientifically and clinically for the benefit of patients across the globe” said Marc Edwards, CEO of Kane Biotech.
“The Institute of Human Virology has been testing the use of bacteriophage therapeutics in treating recalcitrant PJIs with some early signals of success,” explained Dr. Doub, who is also Director of Infectious Diseases Ambulatory Practice at the University of Maryland Medicine Center. “However, DispersinB®, has properties that bacteriophages do not have which include superior application as a preventative therapeutic, broader spectrum of activity, and a much easier regulatory (FDA) path.” Dr. Doub is a consultant for Kane Biotech.
Dr. Nanda Yakandawala, Vice President of Research and Development at Kane, in collaboration with Dr. Doub and Josh Wenke, Ph. D, recently submitted a R-21 grant application to NIH to fund pre-clinical work to be performed by Dr. Wenke.
About University of Texas Medical Department
Established in 1891 as the University of Texas Medical Department, UTMB was the nation's first public medical school and hospital under unified leadership and has evolved into a modern academic health science center with multiple campus locations and almost 1,000 faculty members educating approximately 3,500 students. Since the beginning, UTMB has been at the forefront of medical research, with researchers studying the viruses common to a sub-tropical island climate. Today, our world-renowned investigators generate a portfolio exceeding
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property (81 patents and patents pending, trade secrets, and trademarks) and products developed by the company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
Notes to Editor:
Research Articles
- Kurtz, S.M.; Lau, E.; Watson, H.; Schmier, J.; Parvizi, J. Economic Burden of Periprosthetic Joint Infection in the United States. J. Arthroplast. 2012, 27, 61–65.e1. [CrossRef] [PubMed]
- Natsuhara, K.; Shelton, T.J.; Meehan, J.P.; Lum, Z.C. Mortality During Total Hip Periprosthetic Joint Infection. J. Arthroplast. 2019, 34, S337–S342. [CrossRef] [PubMed
For more information:
| Marc Edwards | Ray Dupuis | ||
| Chief Executive Officer | Chief Financial Officer | ||
| Kane Biotech Inc | Kane Biotech Inc | ||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | ||
| +1 (514) 910-6991 | +1 (204) 298-2200 | ||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What recent collaborations has Kane Biotech announced?
What is the significance of DispersinB® in the treatment of PJIs?
How much do prosthetic joint infections cost the U.S. healthcare system?
What are the implications of the NIH funding for Kane Biotech?
What are the mortality statistics associated with prosthetic joint infections?
